Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
- Written by PR Newswire
Immediately Accretive Combination Creates a Unique Global, Vertically Integrated Biosimilars Leader
![]() |
BENGALURU, India, Feb. 28, 2022 /PRNewswire/ -- Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ: VTRS). Accordingly, Biocon Biologics...